CN1271052C - 磺酰胺衍生物、它们的制备和作为药物的用途 - Google Patents

磺酰胺衍生物、它们的制备和作为药物的用途 Download PDF

Info

Publication number
CN1271052C
CN1271052C CNB028240804A CN02824080A CN1271052C CN 1271052 C CN1271052 C CN 1271052C CN B028240804 A CNB028240804 A CN B028240804A CN 02824080 A CN02824080 A CN 02824080A CN 1271052 C CN1271052 C CN 1271052C
Authority
CN
China
Prior art keywords
indoles
sulphonamide
group
naphthalene
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028240804A
Other languages
English (en)
Chinese (zh)
Other versions
CN1599718A (zh
Inventor
R·梅尔塞－比达尔
B·安达卢斯－马塔罗
J·弗里戈拉－康斯坦莎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of CN1599718A publication Critical patent/CN1599718A/zh
Application granted granted Critical
Publication of CN1271052C publication Critical patent/CN1271052C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Psychiatry (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CNB028240804A 2001-11-14 2002-11-08 磺酰胺衍生物、它们的制备和作为药物的用途 Expired - Fee Related CN1271052C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200102517 2001-11-14
ES200102517A ES2187300B1 (es) 2001-11-14 2001-11-14 Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.

Publications (2)

Publication Number Publication Date
CN1599718A CN1599718A (zh) 2005-03-23
CN1271052C true CN1271052C (zh) 2006-08-23

Family

ID=8499446

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028240804A Expired - Fee Related CN1271052C (zh) 2001-11-14 2002-11-08 磺酰胺衍生物、它们的制备和作为药物的用途

Country Status (33)

Country Link
US (4) US7105515B2 (enExample)
EP (2) EP1666462B1 (enExample)
JP (2) JP4416505B2 (enExample)
KR (1) KR20040071685A (enExample)
CN (1) CN1271052C (enExample)
AR (1) AR037288A1 (enExample)
AT (2) ATE428694T1 (enExample)
BR (1) BR0214243A (enExample)
CA (1) CA2466965C (enExample)
CO (1) CO5590895A2 (enExample)
CY (1) CY1105362T1 (enExample)
DE (2) DE60232029D1 (enExample)
DK (1) DK1445252T3 (enExample)
EC (1) ECSP045105A (enExample)
ES (4) ES2187300B1 (enExample)
HR (1) HRP20040429B1 (enExample)
HU (1) HUP0402317A2 (enExample)
IL (2) IL161885A0 (enExample)
IS (2) IS7263A (enExample)
MA (1) MA27093A1 (enExample)
MX (1) MXPA04004601A (enExample)
NO (1) NO20042478L (enExample)
NZ (2) NZ543393A (enExample)
PL (1) PL373894A1 (enExample)
PT (2) PT1445252E (enExample)
RS (1) RS41104A (enExample)
RU (2) RU2293082C2 (enExample)
SG (1) SG146442A1 (enExample)
SI (1) SI1445252T1 (enExample)
TW (1) TWI275585B (enExample)
UA (1) UA78252C2 (enExample)
WO (1) WO2003042175A1 (enExample)
ZA (1) ZA200404073B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
ATE407671T1 (de) * 2003-05-09 2008-09-15 Esteve Labor Dr Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222829B1 (es) 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222832B1 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2222830B1 (es) 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2228268B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222827B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
MXPA06007415A (es) * 2004-01-02 2007-01-26 Suven Life Sciences Ltd Inden [2, 1a] indenos e isoindol [2,1-a] indoles novedosos.
ES2246721B1 (es) * 2004-08-10 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos.
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
CN101247853B (zh) * 2005-04-13 2014-11-12 轴突公司 具有nos抑制活性的取代的吲哚化合物
JP5026690B2 (ja) * 2005-11-21 2012-09-12 株式会社ジャパンディスプレイイースト 表示装置
CN101374808B (zh) * 2006-01-24 2011-05-25 伊莱利利公司 孕酮受体的吲哚磺酰胺调节剂
EP1837332A1 (en) * 2006-03-23 2007-09-26 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
US7989447B2 (en) * 2006-04-13 2011-08-02 Neuraxon, Inc. 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity
EP1902733A1 (en) * 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
EP1953141A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
EP2018861A1 (en) * 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
ATE495737T1 (de) * 2007-08-01 2011-02-15 Esteve Labor Dr Kombination von mindestens zwei 5-ht6-liganden
EP2036888A1 (en) * 2007-09-17 2009-03-18 Laboratorios del Dr. Esteve S.A. Naphthyl-substituted sulfonamides
JP2011503120A (ja) * 2007-11-16 2011-01-27 ニューラクソン，インコーポレーテッド 内臓痛を治療するためのインドール化合物および方法
AU2008321353A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
MX2010005343A (es) * 2007-11-16 2010-08-09 Neuraxon Inc Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina.
EP2116546A1 (en) * 2008-05-09 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands
EP2116547A1 (en) 2008-05-09 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands
WO2015015378A2 (en) * 2013-08-02 2015-02-05 Pfizer Inc. Rorc2 inhibitors and methods of use thereof
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472870A (en) 1966-08-29 1969-10-14 Mead Johnson & Co Sulfonamidotryptamines
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
PL322843A1 (en) * 1995-03-20 1998-02-16 Lilly Co Eli 5-substituted 3-91,2,3,6-tetrahydropyridin-4-yl)- and 3-9piperydin-4-4-yl0-1h-indoles nevel 5-htif natagonists
US5962473A (en) * 1996-08-16 1999-10-05 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
EP0875513A1 (en) * 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
US6380201B1 (en) * 1997-08-05 2002-04-30 Eli Lilly And Company Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F agonists
ES2187300B1 (es) * 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.

Also Published As

Publication number Publication date
WO2003042175A1 (es) 2003-05-22
TW200407306A (en) 2004-05-16
TWI275585B (en) 2007-03-11
JP5132649B2 (ja) 2013-01-30
ES2187300A1 (es) 2003-05-16
NZ533136A (en) 2006-01-27
DE60209779T2 (de) 2006-11-16
RU2293082C2 (ru) 2007-02-10
HRP20040429A2 (en) 2005-06-30
ES2249129B2 (es) 2007-08-16
RU2004117850A (ru) 2005-11-20
MXPA04004601A (es) 2004-08-13
JP4416505B2 (ja) 2010-02-17
IL161885A0 (en) 2005-11-20
US7176200B2 (en) 2007-02-13
ES2187300B1 (es) 2004-06-16
NZ543393A (en) 2007-04-27
US20070167448A1 (en) 2007-07-19
EP1666462A1 (en) 2006-06-07
US20050032791A1 (en) 2005-02-10
KR20040071685A (ko) 2004-08-12
SI1445252T1 (sl) 2006-06-30
IS7263A (is) 2004-05-13
JP2005513016A (ja) 2005-05-12
ATE428694T1 (de) 2009-05-15
CA2466965A1 (en) 2003-05-22
EP1445252A1 (en) 2004-08-11
RS41104A (sr) 2006-10-27
US20030191124A1 (en) 2003-10-09
CO5590895A2 (es) 2005-12-30
US7105515B2 (en) 2006-09-12
IL193234A0 (en) 2009-02-11
HRP20040429B1 (hr) 2007-10-31
EP1445252B1 (en) 2006-03-08
CA2466965C (en) 2011-09-06
ECSP045105A (es) 2004-07-23
SG146442A1 (en) 2008-10-30
DK1445252T3 (da) 2006-06-19
BR0214243A (pt) 2004-12-21
EP1666462B1 (en) 2009-04-15
IS8698A (is) 2007-12-05
CN1599718A (zh) 2005-03-23
CY1105362T1 (el) 2010-03-03
PT1445252E (pt) 2006-07-31
US20060258653A1 (en) 2006-11-16
ES2322068T3 (es) 2009-06-16
ES2249129A1 (es) 2006-03-16
PL373894A1 (en) 2005-09-19
AR037288A1 (es) 2004-11-03
JP2009298819A (ja) 2009-12-24
ES2259387T3 (es) 2006-10-01
DE60209779D1 (de) 2006-05-04
US7498328B2 (en) 2009-03-03
MA27093A1 (fr) 2004-12-20
ATE319684T1 (de) 2006-03-15
DE60232029D1 (de) 2009-05-28
ZA200404073B (en) 2006-05-31
UA78252C2 (en) 2007-03-15
NO20042478L (no) 2004-08-12
HK1070053A1 (en) 2005-06-10
RU2005136355A (ru) 2007-05-27
HUP0402317A2 (hu) 2005-02-28
US7452881B2 (en) 2008-11-18
PT1666462E (pt) 2009-05-07

Similar Documents

Publication Publication Date Title
CN1271052C (zh) 磺酰胺衍生物、它们的制备和作为药物的用途
CN1720225B (zh) 具有5-羟色胺受体亲和性的n-芳基磺酰-3-取代吲哚及其制备方法和含有其的药物组合物
JP2005501019A (ja) ５−ｈｔ６レセプター親和性を有する４−ピペラジニルインドール誘導体
CN1620290A (zh) 作为5－羟色胺－6配体的吲哚基烷基胺衍生物
CN101068809A (zh) 取代吲哚化合物及其作为5－ht6受体调节剂的用途
CN1863527A (zh) 1－磺酰基吲哚衍生物、其制备及其作为5－ht6配体的用途
EP0470039A2 (en) Novel 3-arylindole and 3-arylindazole derivatives
CN1437597A (zh) 取代的苯基－哌嗪衍生物及其制备和用途
US20050065202A1 (en) Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion
CN1829508A (zh) 吲哚－4磺酰胺衍生物,它们的制备及其作为5－ht－6调节剂的用途
CN100338058C (zh) 新的吲哚衍生物
CN1694866A (zh) 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
CN1832739A (zh) 吲哚－7磺酰胺衍生物及其制备和作为5－ht－6调节剂的用途
US20110092540A1 (en) Substituted n-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands
CN1816334A (zh) 磺酰胺衍生物在制备用于预防和/或治疗食物摄取性疾病的药物中的用途
HK1070053B (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
US20110105555A1 (en) Substituted n-imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060823

Termination date: 20131108